-
2
-
-
84868149988
-
Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA)
-
M.M. Silva, C. Thelwell, S.C. Williams, and C. Longstaff Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA) J Thromb Haemost 10 2012 2354 2360
-
(2012)
J Thromb Haemost
, vol.10
, pp. 2354-2360
-
-
Silva, M.M.1
Thelwell, C.2
Williams, S.C.3
Longstaff, C.4
-
4
-
-
0031915389
-
Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/ thrombomodulin-dependent activation, thermal stability, and enzymatic properties
-
M.B. Boffa, W. Wang, L. Bajzar, and M.E. Nesheim Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties J Biol Chem 273 1998 2127 2135
-
(1998)
J Biol Chem
, vol.273
, pp. 2127-2135
-
-
Boffa, M.B.1
Wang, W.2
Bajzar, L.3
Nesheim, M.E.4
-
5
-
-
0025255189
-
Purification and characterization of a new arginine carboxypeptidase in human serum
-
D. Hendriks, W. Wang, S. Scharpé, M.P. Lommaert, and M. van Sande Purification and characterization of a new arginine carboxypeptidase in human serum Biochim Biophys Acta 1034 1990 86 92
-
(1990)
Biochim Biophys Acta
, vol.1034
, pp. 86-92
-
-
Hendriks, D.1
Wang, W.2
Scharpé, S.3
Lommaert, M.P.4
Van Sande, M.5
-
6
-
-
0028222563
-
Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
-
W. Wang, D.F. Hendriks, and S.S. Scharpé Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen J Biol Chem 269 1994 15937 15944
-
(1994)
J Biol Chem
, vol.269
, pp. 15937-15944
-
-
Wang, W.1
Hendriks, D.F.2
Scharpé, S.S.3
-
7
-
-
84867882712
-
Binding of carboxypeptidase N to fibrinogen and fibrin
-
S. Talens, J.H. Lebbink, J.J. Malfliet, J.A. Demmers, S. Uitte de Willige, and F.W. Leebeek Binding of carboxypeptidase N to fibrinogen and fibrin Biochem Biophys Res Commun 427 2012 421 425
-
(2012)
Biochem Biophys Res Commun
, vol.427
, pp. 421-425
-
-
Talens, S.1
Lebbink, J.H.2
Malfliet, J.J.3
Demmers, J.A.4
Uitte De Willige, S.5
Leebeek, F.W.6
-
9
-
-
42149106757
-
Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity
-
J.B. Walker, T.M. Binette, M. Mackova, G.R. Lambkin, L. Mitchell, and L. Bajzar Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity J Thromb Haemost 6 2008 848 855
-
(2008)
J Thromb Haemost
, vol.6
, pp. 848-855
-
-
Walker, J.B.1
Binette, T.M.2
Mackova, M.3
Lambkin, G.R.4
Mitchell, L.5
Bajzar, L.6
-
10
-
-
0028815556
-
Plasma carboxypeptidases as regulators of the plasminogen system
-
A. Redlitz, A.K. Tan, D.L. Eaton, and E.F. Plow Plasma carboxypeptidases as regulators of the plasminogen system J Clin Invest 96 1995 2534 2538
-
(1995)
J Clin Invest
, vol.96
, pp. 2534-2538
-
-
Redlitz, A.1
Tan, A.K.2
Eaton, D.L.3
Plow, E.F.4
-
11
-
-
48249152233
-
The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate
-
J.W. Weisel, and R.I. Litvinov The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate Cardiovasc Hematol Agents Med Chem 6 2008 161 180
-
(2008)
Cardiovasc Hematol Agents Med Chem
, vol.6
, pp. 161-180
-
-
Weisel, J.W.1
Litvinov, R.I.2
-
12
-
-
78751560568
-
The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: Kinetic and microscopic studies
-
C. Longstaff, C. Thelwell, S.C. Williams, M.M. Silva, L. Szabó, and K. Kolev The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies Blood 117 2011 661 668
-
(2011)
Blood
, vol.117
, pp. 661-668
-
-
Longstaff, C.1
Thelwell, C.2
Williams, S.C.3
Silva, M.M.4
Szabó, L.5
Kolev, K.6
-
13
-
-
25144516748
-
TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: The PRIME Study
-
P.E. Morange, D.A. Tregouet, C. Frere, G. Luc, D. Arveiler, and J. Ferrieres TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study J Thromb Haemost 3 2005 1503 1510
-
(2005)
J Thromb Haemost
, vol.3
, pp. 1503-1510
-
-
Morange, P.E.1
Tregouet, D.A.2
Frere, C.3
Luc, G.4
Arveiler, D.5
Ferrieres, J.6
-
14
-
-
34247275973
-
Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation
-
C. Ladenvall, A. Gils, K. Jood, C. Blomstrand, P.J. Declerck, and C. Jern Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation Arterioscler Thromb Vasc Biol 27 2007 955 962
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 955-962
-
-
Ladenvall, C.1
Gils, A.2
Jood, K.3
Blomstrand, C.4
Declerck, P.J.5
Jern, C.6
-
15
-
-
2342571555
-
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
-
S. Eichinger, V. Schönauer, A. Weltermann, E. Minar, C. Bialonczyk, and M. Hirschl Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism Blood 103 2004 3773 3776
-
(2004)
Blood
, vol.103
, pp. 3773-3776
-
-
Eichinger, S.1
Schönauer, V.2
Weltermann, A.3
Minar, E.4
Bialonczyk, C.5
Hirschl, M.6
-
16
-
-
77955874727
-
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
-
M.E. Meltzer, T. Lisman, P.G. de Groot, J.C. Meijers, S. le Cessie, and C.J. Doggen Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 Blood 116 2010 113 121
-
(2010)
Blood
, vol.116
, pp. 113-121
-
-
Meltzer, M.E.1
Lisman, T.2
De Groot, P.G.3
Meijers, J.C.4
Le Cessie, S.5
Doggen, C.J.6
-
17
-
-
0037383184
-
Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke
-
J. Montaner, M. Ribó, J. Monasterio, C.A. Molina, and J. Alvarez-Sabín Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke Stroke 34 2003 1038 1040
-
(2003)
Stroke
, vol.34
, pp. 1038-1040
-
-
Montaner, J.1
Ribó, M.2
Monasterio, J.3
Molina, C.A.4
Alvarez-Sabín, J.5
-
18
-
-
46749108013
-
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels
-
N. Folkeringa, M. Coppens, N.J. Veeger, V.J. Bom, S. Middeldorp, and K. Hamulyak Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels Thromb Haemost 100 2008 38 44
-
(2008)
Thromb Haemost
, vol.100
, pp. 38-44
-
-
Folkeringa, N.1
Coppens, M.2
Veeger, N.J.3
Bom, V.J.4
Middeldorp, S.5
Hamulyak, K.6
-
19
-
-
1542297149
-
Very high TAFI antigen levels are associated with a lower risk of hard coronary events: The PRIME Study
-
I. Juhan-Vague, P.E. Morange, and PRIME Study Group Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study J Thromb Haemost 1 2003 2243 2244
-
(2003)
J Thromb Haemost
, vol.1
, pp. 2243-2244
-
-
Juhan-Vague, I.1
Morange, P.E.2
Study Group, P.3
-
20
-
-
80052437004
-
Thrombin activatable fibrinolysis inhibitor
-
P.J. Declerck Thrombin activatable fibrinolysis inhibitor Hamostaseologie 31 2011 165 173
-
(2011)
Hamostaseologie
, vol.31
, pp. 165-173
-
-
Declerck, P.J.1
-
21
-
-
3142579973
-
The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability
-
J.B. Walker, and L. Bajzar The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability J Biol Chem 279 2004 27896 27904
-
(2004)
J Biol Chem
, vol.279
, pp. 27896-27904
-
-
Walker, J.B.1
Bajzar, L.2
-
22
-
-
0038029888
-
Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin
-
H. Wang, A. Yu, B. Wiman, and S. Pap Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin Eur J Biochem 270 2003 2023 2029
-
(2003)
Eur J Biochem
, vol.270
, pp. 2023-2029
-
-
Wang, H.1
Yu, A.2
Wiman, B.3
Pap, S.4
-
23
-
-
0036143120
-
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life
-
M. Nagashima, Z.F. Yin, L. Zhao, K. White, Y. Zhu, and N. Lasky Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life J Clin Invest 109 2002 101 110
-
(2002)
J Clin Invest
, vol.109
, pp. 101-110
-
-
Nagashima, M.1
Yin, Z.F.2
Zhao, L.3
White, K.4
Zhu, Y.5
Lasky, N.6
-
25
-
-
0027211110
-
An international collaborative study to investigate standardisation of hirudin potency
-
C. Longstaff, M.Y. Wong, and P.J. Gaffney An international collaborative study to investigate standardisation of hirudin potency Thromb Haemost 69 1993 430 435
-
(1993)
Thromb Haemost
, vol.69
, pp. 430-435
-
-
Longstaff, C.1
Wong, M.Y.2
Gaffney, P.J.3
-
26
-
-
0014932863
-
Plasminogen purification from human plasma by affinity chromatography
-
D.G. Deutsch, and E.T. Mertz Plasminogen purification from human plasma by affinity chromatography Science 170 1970 1095 1096
-
(1970)
Science
, vol.170
, pp. 1095-1096
-
-
Deutsch, D.G.1
Mertz, E.T.2
-
27
-
-
0028360109
-
Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors
-
K. Kolev, I. Léránt, K. Tenekejiev, and R. Machovich Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors J Biol Chem 269 1994 17030 17034
-
(1994)
J Biol Chem
, vol.269
, pp. 17030-17034
-
-
Kolev, K.1
Léránt, I.2
Tenekejiev, K.3
Machovich, R.4
-
28
-
-
0030051895
-
Quantitative comparison of fibrin degradation with plasmin, miniplasmin, neurophil leukocyte elastase and cathepsin G
-
K. Kolev, E. Komorowicz, W.G. Owen, and R. Machovich Quantitative comparison of fibrin degradation with plasmin, miniplasmin, neurophil leukocyte elastase and cathepsin G Thromb Haemost 75 1996 140 146
-
(1996)
Thromb Haemost
, vol.75
, pp. 140-146
-
-
Kolev, K.1
Komorowicz, E.2
Owen, W.G.3
Machovich, R.4
-
29
-
-
0030997702
-
Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation
-
K. Kolev, K. Tenekedjiev, E. Komorowicz, and R. Machovich Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation J Biol Chem 272 1997 13666 13675
-
(1997)
J Biol Chem
, vol.272
, pp. 13666-13675
-
-
Kolev, K.1
Tenekedjiev, K.2
Komorowicz, E.3
Machovich, R.4
-
30
-
-
34250692159
-
Structure of fibrin: Impact on clot stability
-
J.W. Weisel Structure of fibrin: impact on clot stability J Thromb Haemost 5 Suppl. 1 2007 116 124
-
(2007)
J Thromb Haemost
, vol.5
, Issue.SUPPL. 1
, pp. 116-124
-
-
Weisel, J.W.1
-
32
-
-
0019987224
-
Studies on the kinetics of plasminogen activation by tissue plasminogen activator
-
M. Rånby Studies on the kinetics of plasminogen activation by tissue plasminogen activator Biochim Biophys Acta 704 1982 461 469
-
(1982)
Biochim Biophys Acta
, vol.704
, pp. 461-469
-
-
Rånby, M.1
-
33
-
-
40349098341
-
Suppressed catalytic efficiency of plasmin in the presence of long-chain fatty acids. Identification of kinetic parameters from continuous enzymatic assay with Monte Carlo simulation
-
A. Tanka-Salamon, K. Tenekedjiev, R. Machovich, and K. Kolev Suppressed catalytic efficiency of plasmin in the presence of long-chain fatty acids. Identification of kinetic parameters from continuous enzymatic assay with Monte Carlo simulation FEBS J 275 2008 1274 1282
-
(2008)
FEBS J
, vol.275
, pp. 1274-1282
-
-
Tanka-Salamon, A.1
Tenekedjiev, K.2
Machovich, R.3
Kolev, K.4
-
34
-
-
4544232604
-
A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units
-
C. Longstaff, and C.M. Whitton A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units J Thromb Haemost 2 2004 1416 1421
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1416-1421
-
-
Longstaff, C.1
Whitton, C.M.2
-
35
-
-
80052967551
-
Lytic resistance of fibrin containing red blood cells
-
N. Wohner, P. Sótonyi, R. Machovich, L. Szabó, K. Tenekedjiev, and M.M. Silva Lytic resistance of fibrin containing red blood cells Arterioscler Thromb Vasc Biol 31 2011 2306 2313
-
(2011)
Arterioscler Thromb Vasc Biol
, vol.31
, pp. 2306-2313
-
-
Wohner, N.1
Sótonyi, P.2
Machovich, R.3
Szabó, L.4
Tenekedjiev, K.5
Silva, M.M.6
-
36
-
-
0032538557
-
A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
-
W. Wang, M.B. Boffa, L. Bajzar, J.B. Walker, and M.E. Nesheim A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor J Biol Chem 273 1998 27176 27181
-
(1998)
J Biol Chem
, vol.273
, pp. 27176-27181
-
-
Wang, W.1
Boffa, M.B.2
Bajzar, L.3
Walker, J.B.4
Nesheim, M.E.5
-
37
-
-
33646886617
-
Arginine, arginine analogs and nitric oxide production in chronic kidney disease
-
C. Baylis Arginine, arginine analogs and nitric oxide production in chronic kidney disease Nat Clin Pract Nephrol 2 2006 209 220
-
(2006)
Nat Clin Pract Nephrol
, vol.2
, pp. 209-220
-
-
Baylis, C.1
-
38
-
-
0029044322
-
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
-
L. Bajzar, R. Manuel, and M.E. Nesheim Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor J Biol Chem 270 1995 14477 14484
-
(1995)
J Biol Chem
, vol.270
, pp. 14477-14484
-
-
Bajzar, L.1
Manuel, R.2
Nesheim, M.E.3
-
39
-
-
1842728323
-
Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin
-
M. Schneider, N. Brufatto, E. Neill, and M. Nesheim Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin J Biol Chem 279 2004 13340 13345
-
(2004)
J Biol Chem
, vol.279
, pp. 13340-13345
-
-
Schneider, M.1
Brufatto, N.2
Neill, E.3
Nesheim, M.4
-
40
-
-
0035071928
-
Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA
-
M. Colucci, A.M. D'Aprile, A. Italia, P. Gresele, J. Morser, and N. Semeraro Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA Thromb Haemost 85 2001 661 666
-
(2001)
Thromb Haemost
, vol.85
, pp. 661-666
-
-
Colucci, M.1
D'Aprile, A.M.2
Italia, A.3
Gresele, P.4
Morser, J.5
Semeraro, N.6
-
41
-
-
33748589984
-
Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: Sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI)
-
A.H. Guimarães, M.M. Barrett-Bergshoeff, M. Criscuoli, S. Evangelista, and D.C. Rijken Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI) Thromb Haemost 96 2006 325 330
-
(2006)
Thromb Haemost
, vol.96
, pp. 325-330
-
-
Guimarães, A.H.1
Barrett-Bergshoeff, M.M.2
Criscuoli, M.3
Evangelista, S.4
Rijken, D.C.5
-
42
-
-
1642398603
-
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI
-
N.J. Mutch, N.R. Moore, E. Wang, and N.A. Booth Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI J Thromb Haemost 1 2003 2000 2007
-
(2003)
J Thromb Haemost
, vol.1
, pp. 2000-2007
-
-
Mutch, N.J.1
Moore, N.R.2
Wang, E.3
Booth, N.A.4
-
43
-
-
84897585583
-
Modelling fibrinolysis: A 3D stochastic multiscale model
-
10.1093/imammb/dqs029 [in press]
-
B.E. Bannish, J.P. Keener, and A.L. Fogelson Modelling fibrinolysis: a 3D stochastic multiscale model Math Med Biol 2013 10.1093/imammb/dqs029 [in press]
-
(2013)
Math Med Biol
-
-
Bannish, B.E.1
Keener, J.P.2
Fogelson, A.L.3
-
44
-
-
26044469358
-
Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis
-
A. Borgström, and S. Regnér Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis Pancreatology 5 2005 530 536
-
(2005)
Pancreatology
, vol.5
, pp. 530-536
-
-
Borgström, A.1
Regnér, S.2
-
46
-
-
77953786118
-
Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme
-
F. Omodeo-Salè, L. Cortelezzi, Z. Vommaro, D. Scaccabarozzi, and A.M. Dondorp Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme Am J Physiol Cell Physiol 299 2010 C148 C154
-
(2010)
Am J Physiol Cell Physiol
, vol.299
-
-
Omodeo-Salè, F.1
Cortelezzi, L.2
Vommaro, Z.3
Scaccabarozzi, D.4
Dondorp, A.M.5
-
48
-
-
84878311772
-
Thrombin activatable fibrinolysis inhibitor: A putative target to enhance fibrinolysis
-
E. Vercauteren, A. Gils, and P.J. Declerck Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis Semin Thromb Hemost 39 2013 365 372
-
(2013)
Semin Thromb Hemost
, vol.39
, pp. 365-372
-
-
Vercauteren, E.1
Gils, A.2
Declerck, P.J.3
-
49
-
-
42149166603
-
Which carboxypeptidase determines the antifibrinolytic potential?
-
A. Gils Which carboxypeptidase determines the antifibrinolytic potential? J Thromb Haemost 6 2008 846 847
-
(2008)
J Thromb Haemost
, vol.6
, pp. 846-847
-
-
Gils, A.1
|